Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Litx Plus Chemotherapy for Colorectal Cancer Liver Metastases
NCT00440310Phase 3Completed
- Sponsor
- Light Science Oncology
- Start
- Feb 2007
- Primary completion
- May 2011
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of talaporfin sodium in colorectal cancer (CRC) (2 arms), sponsored by Light Science Oncology. Primary endpoint: Overall Survival up to 184 weeks. Started Feb 2007; status: completed.
02
Drugs
talaporfin sodium
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00440310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00440310.